SLRX Stock Risk & Deep Value Analysis
SLRX
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About SLRX Stock
We analyzed SLRX using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran SLRX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Extreme. Here's what we found.
SLRX Risk Analysis & Red Flags
What Could Go Wrong
Investing in SLRX would be equivalent to investing in a phantom stock as the company was acquired and delisted on October 18, 2023. Any 'price' displayed for the ticker is likely erroneous or for historical reference, not a liquid, investable asset with growth potential. Any funds attempted to be invested would be lost.
Risk Matrix
Overall
Extreme
Financial
Not Applicable
Market
Not Applicable
Competitive
Not Applicable
Execution
Not Applicable
Regulatory
Not Applicable
Red Flags
- ⚠
Company is delisted and no longer exists as an independent publicly traded entity.
- ⚠
No independent operations, financials, or management team.
- ⚠
The current quoted price of $7.62 is anomalous and does not represent a tradeable value.
Upcoming Risk Events
- 📅
Not applicable; the primary 'risk' is the non-existence of the independent entity itself.
When to Reconsider
- 🚪
The fundamental status of the company as delisted is the ultimate sell signal. Any position should be liquidated immediately if, for some reason, an investor unknowingly holds it.
Unlock SLRX Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does SLRX (SLRX) Do?
Sector
Healthcare
Industry
Biotechnology
Employees
2
Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. Salarius Pharmaceuticals, Inc. is based in Houston, Texas.
Visit SLRX WebsiteInvestment Thesis
There is no investable thesis for SLRX, as the company was acquired and delisted on October 18, 2023. It does not exist as a standalone publicly traded entity capable of generating 10x returns or any returns. Any investment in this ticker would be speculative and likely result in a complete loss of capital.
Is SLRX Stock Undervalued?
Unlock the full AI analysis for SLRX
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
SLRX Price Targets & Strategy
12-Month Target
$0.00
Bull Case
$0.00
Bear Case
$0.00
Valuation Basis
The company no longer exists as an independent publicly traded entity, thus its intrinsic and market value as a standalone investment is $0.00.
Entry Strategy
Not applicable; SLRX is not an investable asset.
Exit Strategy
Not applicable; avoid any attempt to acquire this delisted ticker.
Portfolio Allocation
0% for all risk tolerances.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does SLRX Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Not Applicable
Not applicable; the company does not exist as an independent entity to possess a moat.
SLRX Competitive Moat Analysis
Sign up to see competitive advantages
SLRX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Not Applicable; no independent company for sentiment.
Institutional Sentiment
Not Applicable; no independent company for institutional interest.
Insider Activity (Form 4)
Not Applicable; no independent company with active insiders.
Options Flow
Normal options activity (meaning non-existent for a delisted ticker).
Earnings Intelligence
Next Earnings
Not applicable; company is delisted.
Surprise Probability
Not Applicable
Historical Earnings Pattern
Not applicable; company is delisted.
Key Metrics to Watch
Competitive Position
Top Competitor
Not Applicable
Market Share Trend
Not applicable; no independent company.
Valuation vs Peers
Not applicable; no independent company to compare.
Competitive Advantages
- •Not applicable; no independent company.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive SLRX Stock Higher?
Near-Term (0-6 months)
- •Not applicable; company is delisted.
Medium-Term (6-18 months)
- •Not applicable; company is delisted.
Long-Term (18+ months)
- •Not applicable; company is delisted.
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for SLRX?
- ✓
Confirming the delisted status.
- ✓
Any official communication regarding VNRX's plans for Salarius assets (though this would relate to VNRX, not SLRX).
Bull Case Analysis
See what could go right with Premium
Competing with SLRX
See how SLRX compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
SLRX SLRX | — | 0.1 | — | — | — | — | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for SLRX (SLRX)?
As of March 29, 2026, SLRX has a DVR Score of 0.1 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What ticker symbol does SLRX use?
SLRX is the ticker symbol for SLRX. The company trades on the NCM.
What is the risk level for SLRX stock?
Our analysis rates SLRX's overall risk as Extreme. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the SLRX DVR analysis updated?
Our AI-powered analysis of SLRX is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 29, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for SLRX (SLRX) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.